Nature Reviews Drug Discovery contents March 2015 Volume 14 Number 3 pp 149-221

Advertisement
NEW WHITE PAPER: Xenograft Host Selection - Important Factors for Experimental SuccessGEMs models are now an integral part of understanding tumor biology, validating in vitro findings, and mimicking disease progression. This Paper explores: Critical elements to in vivostudy design The utilization of spontaneous immune deficient mice GEM model application in Oncology research Download Now
TABLE OF CONTENTS
March 2015 Volume 14 Number 3
Impact Factor37.231 *	In this issue Comment News and Analysis Research Highlights Reviews Correspondence Addendum Also this month  Featured article: Advances in the development of influenza virus vaccines Florian Krammer & Peter Palese
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
nature.com webcasts Nature Publishing Group presents a custom webcast on:Using cellular reprogramming and live cell identification to advance cardiac disease modelling Wednesday 18 March, 8AM PDT, 11AM EDT, 3PM GMT, 4PM CET Register for the webcast and live Q & A session Sponsored by:
Comment: Preclinical target validation using patient-derived cells Aled M. Edwards, Cheryl H. Arrowsmith, Chas Bountra, Mark E. Bunnage, Marc Feldmann, Julian C. Knight, Dhavalkumar D. Patel, Panagiotis Prinos, Michael D. Taylor, Michael Sundström on behalf of the SGC Open Source Target-Discovery Partnershipp149 | doi:10.1038/nrd4565The Structural Genomics Consortium (SGC) and its clinical, industry and disease-foundation partners are launching open-source preclinical translational medicine studies. Abstract | Full Text | PDF
NEWS AND ANALYSIS
Fragile X disappointments upset autism ambitions Asher Mullardp151 | doi:10.1038/nrd4555The clinical failure of two large mGluR5-antagonist programmes in Fragile X syndrome has forced drug developers to rethink trial design and target selection for neurodevelopmental indications. PDF
New twist on antibiotic hunt hits pay dirt Alla Katsnelsonp153 | doi:10.1038/nrd4556Platform probes microbial dark matter, boosting natural-product discovery efforts. PDF
NEWS IN BRIEF Charting the decline of US biomedical research funding Asher Mullardp155 | doi:10.1038/nrd4567 PDF
Roche buys $1 billion majority stake in Foundation Asher Mullardp155 | doi:10.1038/nrd4568 PDF
$215 million precision-medicine initiative takes shape Asher Mullardp155 | doi:10.1038/nrd4569 PDF
BIOBUSINESS BRIEFS Regulatory watch: Efficiency indicators for new drugs approved by the FDA from 2003 to 2013 Rossella Belleli, Roland Fisch & Thomas D. Szucsp156 | doi:10.1038/nrd4563 PDF
BIOBUSINESS BRIEFS Patent watch: US Supreme Court revises patent claim construction standards Kevin Noonanp157 | doi:10.1038/nrd4564 PDF
AN AUDIENCE WITH Mike Varneyp158 | doi:10.1038/nrd4566Mike Varney, the new Head of Genentech Research and Early Development (gRED), discusses the culture of science at Genentech under Roche. PDF
FROM THE ANALYST'S COUCH What does it take to produce a breakthrough drug? Dirk Calcoen, Laura Elias & Xiaomeng Yup161 | doi:10.1038/nrd4570Several breakthrough drugs have recently been approved to treat hepatitis C virus (HCV) infection. To understand what it takes to achieve such success, Calcoen and colleagues analysed attrition rates for HCV drug projects over the last 20 years compared with other indications. PDF
RESEARCH HIGHLIGHTS Fibrotic disease: Fixing a feedback loop in fibrosis p163 | doi:10.1038/nrd4559 PDF Cardiovascular disease: MYDGF promotes heart repair after myocardial infarction p164 | doi:10.1038/nrd4557 PDF Anticancer agents: An alternative route to targeting telomere elongation p164 | doi:10.1038/nrd4558 PDF Cancer stem cells: Targeting the root of cancer relapse p165 | doi:10.1038/nrd4560 PDF Stroke: Meddling with the mind p166 | doi:10.1038/nrd4561 PDF IN BRIEF Infectious diseases: Towards a new class of tuberculosis drugs| Antibody design: Hormone–CDR fusions enhance hormone efficacy | Endometriosis:Suppressing the oestrogen-inflammatory axis | Natural products: Enhancing productionPDF Drug Discovery JOBS of the week Postdoc in Drug Delivery University of North Texas Health Science Center at Fort Worth Postdoctoral Fellowship-Drug Discover Moffitt Cancer Center & Research Institute PhD in Cancer and Genetics: New Drug Therapies Cardiff University Postdoctoral Scholar Position in Bioengineering, Biosensors and Drug Delivery University of California - Irvine Research Scientists Cancer Research UK - MedImmune Alliance More Science jobs from Drug Discovery EVENT RICT 2015: Drug Discovery and Selection - Understanding Targets and Mechanisms 01.07.15 Avignon, France More science events from
Advertisement
Droplet Digital™ PCR (ddPCR™) is leading the wayLast year more than 150 peer-reviewed publications took advantage of Droplet Digital PCR's unmatched ability to detect rare nucleic acid species. From tracking cancer biomarkers to quantifying rare mutations, gene expression, and miniscule viral loads, Droplet Digital PCR led to more discoveries than any other digital PCR platform. Visit our ddPCR page for application guides, publication lists, and webinars that explore the world of ddPCR.
REVIEWS
Advances in the development of influenza virus vaccines Florian Krammer & Peter Palesep167 | doi:10.1038/nrd4529Current influenza vaccines are effective but require reformulation each year and do not protect against pandemic influenza strains. Here, Krammer and Palese discuss the advances in the design and production of seasonal and pandemic influenza virus vaccines, including novel vaccine constructs and adjuvants. Advances in the design of universal influenza vaccines are also presented. Abstract | Full Text | PDF
Unleashing the therapeutic potential of human kallikrein-related serine proteases Ioannis Prassas, Azza Eissa, Gennadiy Poda & Eleftherios P. Diamandisp183 | doi:10.1038/nrd4534Members of the family of kallikrein (KLK)-related proteases are found in various tissues — including the airway, prostate and brain — and have a wide range of functions. The authors describe the roles of KLKs in health and disease, and highlight the small-molecule, peptide-based, protein-based, antibody-based and immunotherapeutic strategies that are being used to target KLKs in certain diseases. Abstract | Full Text | PDF | Supplementary information
Principles in the design of ligand-targeted cancer therapeutics and imaging agents Madduri Srinivasarao, Chris V. Galliford & Philip S. Lowp203 | doi:10.1038/nrd4519One strategy for treating cancer while limiting off-target effects on healthy cells is to conjugate cytotoxic agents to small-molecule ligands for receptors that are upregulated in tumours. Low and colleagues explain the key aspects to be considered when designing ligand–drug conjugates, and summarize the ligand–drug and ligand–imaging agent conjugates that are currently in clinical trials. Abstract | Full Text | PDF
CORRESPONDENCE
Correspondence: Progression-seeking bias and rational optimism in research and development Dennis W. Lendrem, B. Clare Lendrem, Richard W. Peck, Stephen C. Senn, Simon Day & John D. Isaacsp219 | doi:10.1038/nrd4320-c1 Full Text | PDF | Supplementary information
ADDENDUM
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders Katrina J. Falkenberg & Ricky W. Johnstonep219 | doi:10.1038/nrd4579 Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com  More Nature Events